Stock RNAZ TRANSCODE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Real-time Estimate Cboe BZX
Other stock markets
 01:26:45 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.425 USD +7.14% Intraday chart for TransCode Therapeutics, Inc. +74.51% -78.29%
Apr. 22 Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
Apr. 22 Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TransCode Therapeutics : Shareholder Meeting - Form 8-K
PU
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
CI
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
CI
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.
CI
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors
MT
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
AQ
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors
CI
TransCode Therapeutics Reports 2023 Results; Provides Business Update
AQ
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
AQ
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
CI
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
AQ
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
CI
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
AQ
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode?s RIG-I Agonist Immunotherapeutic
CI
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
AQ
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer
MT
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
AQ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
CI
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNAZ Stock
  4. News TransCode Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW